Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: phbolton who wrote (6815)	2/21/2000 11:08:00 AM
From: Hank	Respond to of 10293

It's also my understanding that the FDA and the FTC will be modifying their requirements regarding the labelling of products like Zicam. From now on, clinical studies for over the counter medications and homeopathic remedies will only need to involve 5 or less people, preferably from the same household, to demonstrate efficacy. Furthermore, these studies need not be published in a scientific journal in their entirety. Only an abstract need be published since the rest of the material contained in most journal articles is a waste of paper anyway. In this way, the FDA and the FTC hope to speed up the availability of ground breaking medications like Zicam. It's the new and improved fast track approval process.